Carcinogenesis Advance Access originally published online on December 20, 2006
Carcinogenesis 2007 28(3):507-518; doi:10.1093/carcin/bgl253
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The molecular epidemiology of lung cancer
Population Studies and Prevention Program, Karmanos Cancer Institute, and Department of Internal Medicine, Wayne State University School of Medicine, 110 E. Warren Avenue, Detroit, MI 48103, USA
* To whom correspondence should be addressed. Tel: +313 833 0715 ext. 2024; Fax: +313 833 7806; Email: schwarta{at}karmanos.org
Lung cancer is the leading cause of cancer mortality worldwide. There have been only slight improvements in early diagnosis and survival, reflecting limited advances in screening and treatment for lung cancer. The identification of host differences in susceptibility to lung carcinogens, in particular to cigarette smoke, is essential in predicting who is at highest risk. Susceptibility differences in the form of rare, high-penetrance genes are suggested from studies of familial aggregation of lung cancer and a linkage study. Studies focused on more common, low-penetrance genes in the tobacco smoke metabolism pathways (phase I and phase II enzymes) and DNA repair pathways are reviewed, as are inflammation and cell cycle-related genes and DNA adducts as intermediate biomarkers. Also reviewed are studies of epigenetic mechanisms, such as methylation, as alternative sources of variation in host susceptibility. Studies of molecular epidemiology in lung cancer survival are discussed briefly. In the future, studies that focus on complex interactions between multiple genes and environmental exposures within pertinent pathways are needed. New technological advances in genotyping will help move the field forward.
Abbreviations: ADPRT, adenosine diphosphate ribosyl transferase; BER, base excision repair; CI, confidence interval; COX2, cyclooxygenase-2; GSEC, Genetic Susceptibility to Environmental Carcinogenesis; GST, glutathione S-transferase; HR, hazard ratio; IL, interleukin; MDM2, mouse double minute 2; mEH, microsomal epoxide hydrolase; MMPs, matrix metalloproteinases; MPO, myeloperoxidase; NER, nucleotide excision repair; NQO1, NAD(P)H quinone oxidoreductase 1; NSCLC, non-small-cell lung cancer; OR, odds ratio; RR, relative risk; SNP, single-nucleotide polymorphism; SOD, superoxide dismutase
Received August 2, 2006; revised December 15, 2006; accepted December 17, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Hecht, P. W. Villalta, and J.B. Hochalter Analysis of phenanthrene diol epoxide mercapturic acid detoxification products in human urine: relevance to molecular epidemiology studies of glutathione S-transferase polymorphisms Carcinogenesis, May 1, 2008; 29(5): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Kong, X. Wang, W. Xu, S. Behera, G. Hellermann, A. Kumar, R. F. Lockey, S. Mohapatra, and S. S. Mohapatra Natriuretic Peptide Receptor A as a Novel Anticancer Target Cancer Res., January 1, 2008; 68(1): 249 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L. Crawford, T. Blomquist, D.N. Mullins, Y. Yoon, D.R. Hernandez, M. Al-Bagdhadi, J. Ruiz, J. Hammersley, and J.C. Willey CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions Carcinogenesis, December 1, 2007; 28(12): 2552 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Paleari, P. Granone, A. Grozio, A. Cesario, and P. Russo Commentary: Early Diagnosis of Lung Cancer: Where Do We Stand? Oncologist, December 1, 2007; 12(12): 1433 - 1436. [Full Text] [PDF]
|
|